Maxx Orthopedics, Inc. a subsidiary of Maxx Medical, Pvt. Ltd., with offices in the U.S., Singapore, and India, has announced first-in-man surgery for its new Libertas Hip System…and all went well, says Maxx.
First-in-Man for Libertas Hip System
1 min read Premium comments
Secondary#acetabularcup#femoralstems#libertassystem
Dr. Sridhar Durbhakula of OrthoBethesda, in Maryland, performed the case. He told OTW, “I couldn’t be more excited about the new Libertas Hip offered by Maxx Orthopedics. The instrumentation is efficient and allows minimally invasive exposure for a perfect clinical result. The implant technology has a proven track record. I am looking forward to help refine the instrumentation and to help expand the hip implant portfolio to offer the most comprehensive THA product line available.”
The company said, “…The overall design geometry of the implants facilitates a congruent transfer of the weight load and restoring the range of motion. The system comprises of both cemented and cementless femoral stems, cementless acetabular cups designed to be used with highly crosslinked polyethylene modular liners and a choice of either Biolox delta or cobalt chrome head options in multiple head diameters and offset options. The range of component and size options enables surgeons to provide patients with a robust hip arthroplasty solution without compromise.”
Anand Bala, VP of Product for Maxx Orthopedics, told OTW, “The Libertas System offers a comprehensive set of instruments that facilitates the repeatable placement of the implants with due considerations for anatomical variations and the different surgical approaches. Modular instruments that can be easily configured to accommodate the different implant options allow for an easy and efficient trialing of the components before the final implantation.”
“As we enter the hip replacement segment with this launch, we would like the surgeons to know that we are diligently working towards designing additional implant and instrument options that will lead to the creation of a comprehensive hip implant portfolio. True to our mission statement, we are focused on providing new and innovative solutions towards restoring mobility in patient and equipping surgeons with a comprehensive array of instruments and implant options.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.